|Day Low/High||52.26 / 53.16|
|52 Wk Low/High||58.46 / 82.15|
It has become almost too onerous to own something that could be in Amazon's crosshairs.
The consumer is alive, well, and might benefit from a thaw with China and easy to get jobs. So would Boeing and Caterpillar.
Look at the entirety of your portfolio and make sure there are no earnings blow-ups coming from the companies that you own.
As I sit down to eat some lunch and gather my thoughts for the afternoon, here are some of the items I'll be reading up on: · Outgoing FDA chief Scott Gottlieb raises 'concern' over Walgreens Boosts Alliance, Inc. , and CVS Health Corp. selling CBD...
I have had to think long and hard about Lyft, the stock, not the ride-sharing company.
In fact, the de-emphasizing of cigarettes was blamed for declining same store sales.
The contagion in pharmacy stocks is spreading and secular trends aren't helping to find a solution anytime soon.
Might this be the bottom? It might.
Walgreens weak guidance is sending shares plummeting on Tuesday.
While today's action isn't attractive, we were ripe for a little profit-taking.
While the two companies seem very similar on the surface, CVS and Walgreens are different stocks for different types of investors.
I think sometimes the best way to parse the temperament is to go over the most obviously 'wrong' moves and address why they might not be wrong at all.
With all the unknowns surrounding Boeing it's way too early to take a position in the aircraft maker; the same is not true with CVS.
National security is job one. Cutting a nice deal with China that benefits both sides must come second.
This is hope, not fact -- don't pay more for the same old thing.
The market's reaction to the pharmacy giant's acquisition of Aetna is providing a rare opportunity to buy a quality company at a value price.
Why am I not more worried about a recession? Because Fed Chair Jay Powell has our back.
The market rally may be a rising tide, but investors should be wary of some of the stocks it has lifted up.
This is one where many shareholders can no longer take the pain and will sell at all costs.
CVS' spending spree has developed a deep debt issue for the company.
Pharmacy Benefit Managers (PBMs) are in for some problems if proposed regulation is given approval.
A period of repair will be needed before CVS looks attractive on the charts.
A shortened week still brings key economic numbers and earnings results.